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Antiproliferative activityA one-pot synthesis of osmium(IV) complexes with two different tautomers of indazole, 1H-indazole and
2H-indazole, namely (H2ind)[OsIVCl5(2H-ind)] (1) and (H2ind)[OsIVCl5(1H-ind)] (2) is reported. Both
compounds have been comprehensively characterized by NMR spectroscopy, ESI (electrospray ionization)
mass spectrometry, electronic absorption spectroscopy, IR spectroscopy, cyclic voltammetry and tested for
antiproliferative activity in vitro in three human cancer cell lines, CH1 (ovarian carcinoma), A549 (non-
small cell lung cancer) and SW480 (colon carcinoma), as well as in vivo in a Hep3B SCID mouse xeno-
transplantation model. 2H-Indazole tautomer stabilization in 1 has been conﬁrmed by X-ray diffraction.
© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Indazoles are rare in nature, and so far only three natural products
based on an indazole ring have been isolated [1]. These are the inda-
zole alkaloids nigellicine [2], nigeglanine [3], and nigellidine [4]. The
total syntheses of nigellicine and nigeglanine are also well documen-
ted [5,6]. The indazole ring system is of much current interest as
partial structure of a large number of biologically active compounds.
Different aspects of pharmaceutical and other useful applications of
indazoles have been reviewed [7,8]. Some substituted indazoles ex-
hibit relevant biological properties for development as anticancer
drugs [9–15]. One of the tetrasubstituted indazoles, namely, CI-958,
entered clinical trials for prostate cancer treatment about a decade
ago [16]. From the unsubstituted indazole derivatives the most
prominent example is the ruthenium(III) compound (H2ind)[trans-
RuIIICl4(Hind)2] (KP1019, Hind = 1H-indazole), which is now in
clinical trials as an anticancer agent against metastatic solid tumors
[17,18]. Of potential interest are also complexes closely related to
(H2im)[trans-RuIIICl4(DMSO)(Him)] (NAMI-A, Him = imidazole)
[19], an investigational drug which is currently evaluated in a clin-
ical phase II trial for its capacity of inhibiting the process of metas-
tasis, namely (H2ind)[trans-RuIIICl4(DMSO)(Hind)] [20] and its
osmium counterpart [21].on).
NC-ND license.The indazole heterocycle is normally referred to as 1H-indazole, al-
though it has two other potential tautomers 2H-indazole and 3H-indazole
(Chart 1).
The 1H-indazole was found to be the dominant tautomer in the
gaseous state and in aqueous solution, and this result is not reversed
in the excited state by a solvent effect [1,7]. X-ray diffraction studies
of N-unsubstituted indazoles conﬁrm the general preference for 1H-
tautomers in the solid state [22–30]. 1H-Indazoles have benzenoid
properties (are aromatic in nature), while 2-substituted 2H-indazoles
have ortho-quinoid character [31,32]. 3H-Indazoles lack heteroaro-
matic character and are very rare [33].
There is some evidence regarding the inﬂuence of the tautomeric
equilibrium in indazoles on the different biological properties [34–38].
However, the effect of tautomer identity on the antiproliferative ac-
tivity, biological mechanisms involved, and other physico-chemical
properties, which can have an impact on pharmacokinetic andChart 1. The tautomers of indazole.
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indazole remains unexplored.
Hereinwe report on the one-pot synthesis of two complexes, (H2ind)
[OsIVCl5(2H-ind)] (1) and (H2ind)[OsIVCl5(1H-ind)] [39] (2). Stabiliza-
tion of the 2H-form of indazole and binding to osmium(IV) via nitrogen
atom N1 was found in 1. This is only the second example of indazole
coordination via N1 to a transitionmetal ion [40]. In addition, we studied
the stability of both isomers in aqueous solution and compared their
antiproliferative activity in vitro in three human cancer cell lines CH1
(ovarian carcinoma), SW480 (colon carcinoma) and A549 (non-small
cell lung cancer) and in vivo in a Hep3B SCID mouse xeno-transplantation
model in order to establish whether tautomer identity in 1 and 2 has any
effect on biological properties. The antiproliferative activity of (H2ind)
[OsIVCl5(2H-ind)] (1)was found tobe superior to that of (H2ind)[OsIVCl5(1-
H-ind)] (2) in one of three human cancer cell lines applied but inferior in
the in vivo xeno-transplantation model.
2. Experimental section
2.1. Materials
The starting compounds [(DMSO)2H]2[OsCl6] [41,42] and (H2ind)2
[OsCl6] [43] were synthesized as previously reported in the literature.
OsO4 (99.8%) and N2H4·2HCl were purchased from Johnson Matthey
and Fluka, correspondingly, while 1H-indazole was from Aldrich. All
these chemicals were used without further puriﬁcation. (H2ind)
[OsCl5(2H-Hind)] (1) and (H2ind)[OsCl5(1H-Hind)] (2) were prepared
under argon atmosphere using standard Schlenk techniques (Chart 2).
2.2. Synthesis of (H2ind)[OsCl5(κN1-2H-ind)] (1) and
(H2ind)[OsCl5(κN2-1H-ind)] (2)
A suspension of (H2ind)2[OsCl6] (100 mg, 0.16 mmol) in ethanol
(2 ml)was heated in a Schlenk tube at 100 °C (oil bath) for 2 h. After cool-
ing to room temperature the violet precipitate of 1wasﬁltered off, recrys-
tallized from water/acetone (1:1), and dried in vacuo. Yield of 1: 27 mg,
27%. By reducing the volume of the ﬁltrate to one half a brown solid of
2 was formed. This was ﬁltered off, washed with cold ethanol (2 ml)
and dried in vacuo. Yield of 2: 22 mg, 22%. Analytical data for 1: Anal.
Calcd for C14H13Cl5N4Os∙H2O (1∙H2O) (Mr=622.79 g/mol): C, 27.00; H,
2.43; N, 9.00. Found: C, 27.41; H, 2.56; N, 8.85. ESI-MS in MeOH (nega-
tive): m/z 485 [OsIVCl5(Hind)]−, 367 [OsIVCl5]−, 333 [OsCl4]−. MIR,
cm−1: 603, 626, 664, 736, 784, 846, 872, 928, 978, 1077, 1136, 1181,
1238, 1309, 1382, 1441, 1505, 1584, 1618, 2348, 2933, 2975, 3135, 3487
and 3547. FIR, cm−1: 159, 171, 203, 223, 283, 293, 308, 319, 350, 398,
427, 443, 537, 561 and 614. UV–vis (H2O), λmax, nm (ε, M−1 cm−1):
288 (10 095), 362 (8 912), 406 sh (3 236), 560 (5 075), 598 (4 443).
UV–vis (THF), λmax, nm (ε, M−1 cm−1): 367 (9 147), 408 sh (3 996),
518 (3 853), 593 (326). UV–vis (DMF), λmax, nm (ε, M−1 cm−1): 368Chart 2. Compounds rep(10 000), 408 sh (3 949), 510 (4 080), 595 (251). UV–vis (DMSO), λmax,
nm (ε, M−1 cm−1): 367 (5 687), 409 sh (2 752), 521 (2 794), 597
(304). 1H NMR (DMSO-d6, 500.32MHz): δ −14.54 (s, 1H, H3), −0.43
(t, 1H, J=7.67 Hz, H6), 2.81 (d, 1H, J=8.56 Hz, H4), 4.52 (d, 1H,
J=8.83 Hz, H7), 6.66 (t, 1H, J=6.91 Hz, H5), 7.11 (t, 1H, J=7.19 Hz,
H5′), 7.34 (t, 1H, J=7.34 Hz, H6′), 7.54 (d, 1H, J=8.42 Hz, H7′), 7.76 (d,
1H, J=8.12 Hz, H4′), 8.07 (s, 1H, H3′), 14.25 (s, 1H, H2) ppm. 13C{1H}
NMR (DMSO-d6, 125.82 MHz): δ 58.55 (C9), 99.06 (C7), 104.60 (C5),
110.56 (C7′), 120.67 (C5′), 120.98 (C4′), 123.22 (C9′), 126.41 (C6′), 133.82
(C3′), 140.32 (C8′), 157.09 (C4), 177.15 (C6), 184.29 (C8), 299.7 (C3)
ppm. 15NNMR (DMSO-d6, 50.70 MHz): δ 85.9 (N2) ppm. Suitable crystals
of 1·H2O for X-ray diffraction study were grown from a solution of 1 in
DMSO.
Analytical data for 2: ESI-MS in MeOH (negative):m/z 485 [OsIVCl5
(Hind)]−, 367 [OsIVCl5]−. UV–vis (H2O), λmax, nm (ε, M−1 cm−1): 250
(11 134), 257 (10 982), 271 (10 841), 279 (11 395), 284 (11 751) 294 sh
(9 593), 358 (8 882), 401 sh (4 770), 449 sh (2 411), 556 (669), 594
(632). UV–vis (THF), λmax, nm (ε, M−1 cm−1): 253 (10 264), 287 (12
955), 294 sh (11 844), 365 (9 728), ~510 sh (356). UV–vis (DMF),
λmax, nm (ε, M−1 cm−1): 287 (15 146), 294 sh (13297), 366 (12
140), ~510 sh (244). UV–vis (DMSO), λmax, nm (ε, M−1 cm−1):
285 (11 680), 295 sh (9 562), 364 (8 249), 514 (503), 596 (51).
UV–vis (MeOH), λmax, nm (ε, M−1 cm−1): 249 (9 450), 284 (12
152), 293 (10 019), 361 (8 780), 524 (562). 1H NMR (DMSO-d6,
500.32 MHz): δ −4.54 (s, 1H, H3), 3.06 (t, 1H, J=7.7 Hz, H6), 5.90
(d, 1H, J=7.5 Hz, H4), 7.11 (t, 1H, J=7.4 Hz, H5′), 7.34 (t, 1H,
J=7.6 Hz, H6′), 7.53 (d, 1H, J=8.4 Hz, H7′), 7.76 (d, 1H, J=8.1 Hz,
H4′), 8.07 (s, 1H, H3′), 8.23 (t, 1H, J=7.6 Hz, H5), 10.85 (d, 1H,
J=8.5 Hz, H7), 17.76 (s, 1H, H1) ppm. The analytical data for 2
were identical with those reported previously for the same com-
pound prepared via three-step synthesis [39].
2.3. Physical measurements
Elemental analyseswere performedby theMicroanalytical Laboratory
of the Faculty of Chemistry of the University of Vienna. MIR spectra were
measured byusing anATRunitwith a Perkin-Elmer 370 FTIR 2000 instru-
ment (4000–400 cm−1). FIR spectra were recorded on the same instru-
ment in transmission mode using CsI-pellets. UV–vis spectra were
measured on a Perkin-Elmer Lambda 20 UV–vis spectrophotometer
using samples dissolved in DMSO, DMF (dimethylformamide), THF (tet-
rahydrofuran), water or methanol. Electrospray ionization mass spec-
trometry was carried out with a Bruker Esquire 3000 instrument
(Bruker Daltonics, Bremen, Germany) by using methanol and
water as solvents. Expected and measured isotope distributions
were compared. The X-band EPR spectra were recorded on a mod-
iﬁed Varian E-4 spectrometer (Chicago, Roosevelt University).
Cyclic voltammograms were measured in a three-electrode cell
using a 2 mm diameter glassy carbon disk working electrode, aorted in this work.a.
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containing 0.1 M AgNO3. Measurements were performed at room
temperature using an EG&G PARC potentiostat/galvanostat model
273A. Deareation of solutions was accomplished by passing a stream of
argon through the solution for 5 min prior to the measurement and
thenmaintaining a blanket atmosphere of argon over the solution during
themeasurement. The potentials weremeasured in 0.2 M (n-Bu4N)[BF4]/
DMSO using [Fe(η5-C5H5)2] (E1/2ox =+0.68 V vs NHE (normal hydrogen
electrode)) [44] as internal standard and are quoted relative to NHE.
The 1H, 13C and 15N NMR spectra were recorded at 500.32, 125.82 and
50.70 MHz on a Bruker DPX500 (Ultrashield Magnet) in DMSO-d6. 2D
13C,1H HSQC,15N,1H HSQC (heteronuclear single quantum coherence),
13C,1H HMBC (heteronuclear multi-bond correlation spectroscopy) and
1H,1HCOSY (correlation spectroscopy) experimentswere also performed.
2.4. Crystallographic structure determination
X-ray diffractionmeasurement was carried out on a Bruker X8 APEXII
CCD diffractometer. Single crystal of 1·H2O was positioned at 40 mm
from the detector, and 972 frames were measured, each for 20 s over 1°
scan width. The data was processed using SAINT software [45]. Crystal
data, data collection parameters, and structure reﬁnement details are
given in Table 1. The structure was solved by direct methods and reﬁned
by full-matrix least-squares techniques. Os, Cl and O atoms were reﬁned
with anisotropic displacement parameters, while C and N atoms isotropi-
cally. H atomswere inserted in calculatedpositions and reﬁnedwith a rid-
ingmodel. The coordinated 2H-indazole was found to be disordered over
two positions related by a plane of symmetry through Os1, three chloride
ligands, atoms N1 and C1. The indazolium cation was found to be
disordered over four symmetry related (pairwise) positions. The follow-
ing software programs and computer were used: structure solution,
SHELXS-97; reﬁnement, SHELXL-97 [46]; molecular diagrams, ORTEP-3
[47]; computer, Intel CoreDuo.
2.5. Cell lines and culture conditions
CH1 (ovarian carcinoma, human) cells were donated by Lloyd R.
Kelland (CRC Centre for Cancer Therapeutics, Institute of Cancer Re-
search, Sutton, U.K.). A549 (non-small cell lung cancer, human) and
SW480 (colon carcinoma, human) cells were kindly provided by
Brigitte Marian (Institute of Cancer Research, Department of Medi-
cine I, Medical University of Vienna, Austria). Cells were grown in
75 cm2 culture ﬂasks (Iwaki/Asahi Technoglass) as adherentmonolayer
cultures in minimal essential medium (MEM) supplemented with 10%Table 1
Crystal data and details of data collection for 1·H2O.
1·H2O
Empirical formula C14H15Cl5N4OOs
Fw 622.75
Space group Cmc21
a [Å] 7.1253(4)
b [Å] 26.669(2)
c [Å] 9.8100(5)
V [Å3] 1864.1(2)
Z 4
λ [Å] 0.71073
ρcalcd [g cm−3] 2.219
Crystal size [mm3] 0.40×0.20×0.05
T [K] 100
μ [mm−1] 7.568
R1
a 0.0428
wR2
b 0.1068
GOFc 1.094
a R1=Σ||Fo|− |Fc||/Σ|Fo|.
b wR2={Σ[w(Fo2−Fc2)2]/Σ[w(Fo2)2]}1/2.
c GOF={Σ[w(Fo2−Fc2)2]/(n−p)}1/2, where n is the number of re-
ﬂections and p is the total number of parameters reﬁned.heat-inactivated fetal bovine serum, 1 mM sodium pyruvate and
2 mM L-glutamine (all purchased from Sigma-Aldrich) without antibi-
otics. Cultures were maintained at 37 °C in a humidiﬁed atmosphere
containing 5% CO2 and 95% air.
2.6. Cytotoxicity in cancer cell lines
Cytotoxicity in the cell lines mentioned above was determined by
the colorimetric MTT assay (MTT=3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide, purchased from Fluka). For this
purpose, cells were harvested from culture ﬂasks by trypsinization
and seeded in 100 μl/well aliquots in MEM supplemented with 10%
heat-inactivated fetal bovine serum, 1 mM sodium pyruvate, 4 mM
L-glutamine and 1% non-essential amino acids (100×) into 96-well
microculture plates (Iwaki/Asahi Technoglass) in the following densi-
ties, to ensure exponential growth of untreated controls throughout
the experiment: 1.5×103 (CH1), 4.0×103 (A549) and 2.5×103
(SW480) viable cells per well. Cells were allowed to settle and re-
sume proliferation for 24 h and were then exposed to the test com-
pounds by addition of 100 μl/well aliquots of appropriate dilutions
in the same medium. After exposure for 96 h, medium was replaced
by 100 μl/well RPMI 1640 medium (supplemented with 10% heat-
inactivated fetal bovine serum and 4 mM L-glutamine) plus 20 μl/
well solution of MTT in phosphate-buffered saline (5 mg/ml) (all pur-
chased from Sigma-Aldrich). After incubation for 4 h, medium/MTT
mixtures were removed, and the formazan formed by viable cells
was dissolved in DMSO (150 μl/well). Optical densities at 550 nm
(corrected for unspeciﬁc absorbance at 690 nm) were measured
with a microplate reader (Tecan Spectra Classic) to yield relative
quantities of viable cells as percentages of untreated controls, and
50% inhibitory concentrations (IC50) were calculated by interpolation.
Evaluation is based on at least two independent experiments, each
comprising triplicate samples.
2.7. Animals
Six- to eight-week-old female CB-17 scid/scid (SCID) mice were
purchased from Harlan Laboratories (San Pietro al Natisone, Italy).
The animals were kept in a pathogen-free environment and every
procedure was done in a laminar airﬂow cabinet. Experiments were
carried out according to the Austrian and FELASA guidelines for ani-
mal care and protection.
2.8. Xenograft experiments
Hep3B cells (106) were injected (RPMI with 10% matrigel) subcu-
taneously into the right ﬂank. Therapy was started when tumor nod-
ules reached a mean size of 25 mm3. Animals were treated with 1 and
2 (20 mg/kg dissolved in 0.9% NaCl before administration ﬁve times a
week for two weeks). Animals were controlled for distress develop-
ment every day and tumor size was assessed regularly by caliper
measurement. Tumor volume was calculated using the formula:
(length×width2)/2. The drug effect was assessed by determining
the tumor volume on day 25 and day 40.
3. Results and discussion
3.1. Synthesis
In our previous work [39] we described the synthesis of (azole)
pentachloridoosmium(IV) complexes by exploring the Anderson
rearrangement reaction (Hazole = azole heterocycle):
H2azoleð Þ2 OsIVCl6
h i
→
−HCl
H2azoleð Þ OsIVCl5 Hazoleð Þ
h i
→
−HCl
OsIVCl4 Hazoleð Þ2
h i
:
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cohols (85–130 °C) led to the formation of disubstituted products.
Therefore, to quench the Anderson rearrangement after the ﬁrst step,
we carried out the reaction in the presence of tetrabutylammonium
chloride. We succeeded to obtain (n-Bu4N)[OsIVCl5(Hazole)] salts
in boiling ethanol for 1H-pyrazole, 1H-indazole, 1H-benzimidazole,
1H,2,4-triazole in 24, 70, 79, and 33% yield, correspondingly. Imidazole
analog was synthesized in isoamyl alcohol at 100 °C in minor yield,
whereas in boiling ethanol {(n-Bu4N)2[OsIVCl6]}2·[OsIVCl4(Him)2]
(Him = 1H-imidazole)was formed. The synthesis of (n-Bu4N)[OsIVCl5(-
Hbzim)] (Hbzim = 1H-benzimidazole) was accompanied by concurrent
formation of trans-[OsIVCl4(Hbzim)2].
The coordination mode of indazole in (n-Bu4N)[OsIVCl5(Hind)], its
sodium and indazolium salts was established by X-ray diffraction and
NMR spectroscopy. This ﬁnding was in accord with a number of well-
documented crystallographic studies, in which coordination of indazole
to the metal ion takes place via the N2 nitrogen (in nomenclature terms
used for 1H-indazole). Surprisingly, we have discovered now that the
Anderson rearrangement reaction of (H2ind)2[OsIVCl6] results in the for-
mation of two isomers, (H2ind)[OsIVCl5(2H-ind)] (1) and (H2ind)
[OsIVCl5(1H-ind)] (2) (Chart 2). The 2H-form of indazole in 1 is bound
to osmium(IV) via nitrogen atom N1 (vide infra). To the best of
our knowledge this is a second case of stabilization of 2H-formof indazole
and its coordination to metal ions via N1 documented in the literature
[40]. The synthesis and separation of the two isomers are straightforward
and can be performed in a single step avoiding unnecessary intermediate
transformations making these complexes available for comparative bio-
logical investigations.3.2. Crystal structure
The crystal structure of 1·H2O contains an essentially octahe-
dral complex [OsIVCl5(2H-ind)]− (Fig. 1). The complex crystal-
lized in the orthorhombic space group Cmc21. The asymmetric
unit consists of half an anion, half a cation (disordered over two
positions) and half a water molecule which are related with the
corresponding second half by a plane of symmetry. It should be
noted that the coordinated indazole is out of the symmetry
plane and is therefore disordered over two positions as shown
in Fig. 1. The indazolium cation is disordered over four (pairwise)
symmetry related positions. The observed disorder in the crystal
structure of 1·H2O makes a close comparison of geometrical param-
eters of [OsIVCl5(2H-ind)]− and [OsIVCl5(1H-ind)]− irrelevant. There-
fore only a few parameters are quoted in Table 2.Fig. 1. The structure of the complex anions in 1 (left) and in (n-Bu4N)[OsIVCl5(1H-ind)]
(right). The coordinated 2H-indazole is disordered over two positions related by a
plane of symmetry through Os1, three chlorido ligands, atoms N1 and C1.The Os\Cl bonds in 1 and in (n-Bu4N)[OsIVCl5(1H-ind)] [39] are
commonly signiﬁcantly longer than in (Ph4P)[OsVCl6] [48] at 2.252(4)–
2.295(2) or (Et4N)[OsVCl6] [49] at 2.295(3)–2.308(2)Å and well compa-
rable to those in (HPPh3)2[OsIVCl6]∙DMF [50] at 2.330(5)–2.340(5)Å.
Indazole acts mainly as a monodentate neutral ligand in metal
complexes binding to metal ions via N2. In a few cases, it was found
to be deprotonated, acting as a bridging ligand in polynuclear metal
complexes [51,52] or even more rarely as a monodentate indazolate
ligand coordinated via N1 or N2 [53,54].
3.3. EPR measurements
Compound 1was investigated by X-band EPR spectroscopy at 77 K
in 1:1 v/v DMF/MeOH solution (8 mM). A very weak, nearly axial EPR
signal was observed (Supporting Information, Fig. S1) with g=2.64(1),
2.53(1), 2.03(5), which resembles signals seen for ruthenium(III) ana-
logs [55], as well as for other low-spin d5 complexes [56,57]. We attri-
bute this signal to residual osmium(III) side material. EPR studies of
authentic osmium(III) complexes are in progress. No signals due to
osmium(IV) or any other paramagnetic species (e.g., organic radicals)
were observed. A detailed investigation of the magnetic and electronic
properties of the Os(IV) complexes described herein is in progress and
will be reported separately, as it is beyond the scope of the present study.
3.4. NMR spectra
It should be also stressed that both compounds remain intact
in dimethylsulfoxide and the coordination mode can easily be
established by NMR spectroscopy. The 1H and 13C NMR spectra show
signals due to the H2ind+ cation and the coordinated indazole hetero-
cycle. The integration is equal for each detected proton signal of both
the coordinated indazole ligand and the indazolium cation.
The 1H NMR spectrum of the H2ind+ cation is well resolved and
shows, as expected, a singlet at 8.07 (H3′), two doublets at 7.76
(H4′) and 7.54 (H7′) and two triplets at 7.11 (H5′) and 7.34 (H6′) ppm.
The signals of the coordinated indazole are markedly upﬁeld
shifted to negative values, especially for the protons which are closer
to the (low-spin d4) osmium(IV) metal center, which presumably
possesses marked temperature-independent paramagnetism. How-
ever, it should be noted that the signals appear almost as sharp as
in diamagnetic compounds. The multiplicity of ligand 1H signals is
the same as for the metal-free indazole but the order in which they
appear changes due to coordination to the osmium atom.
From the 15N,1H HSQC plot of 1 the H2 is seen at 14.25 ppm (Sup-
porting Information, Fig. S2). A poorly resolved signal of C3 was
detected in 13C,1H HSQC plot at 299.7 ppm, whereas its proton (H3)
at −14.54 ppm. The cross-peak of C3 with H4 permits to assign two
doublets (H4 is at 2.81 and H7 at 4.52 ppm). Protons H4 and H7
show a coupling in 1H, 1H COSY plot with H5 (6.66 ppm) and H6
(−0.43 ppm), correspondingly (Supporting Information, Fig. S3).
Therefore four CH resonances of benzene ring are at 99.06 (C7),
104.60 (C5), 157.09 (C4), and 177.15 (C6) ppm. The quaternary carbon
at 184.29 ppm (C8) displays cross-peaks with H4 and H6, whereas the
signal at 58.55 ppm (C9) couples with H5 and H7 as can be seen in the
13C,1H HMBC plot (Supporting Information, Fig. S4).
The 1H NMR spectra of the coordinated to osmium(IV) 1H-indazole
and its 2H-tautomer differ signiﬁcantly. In particular the chemical shiftTable 2
Selected bond distances (Å) in (H2ind)[OsIVCl5(2H-ind)] (1) and in (n-Bu4N)
[OsIVCl5(1H-ind)] [39].
Atom1–atom2 1 (n-Bu4N)[OsIVCl5(1H-ind)]
Os–N1/Os–N2 2.067(13) 2.068(3)
Os–Claxial 2.353(4) 2.3332(10)
Os–Clequatorial(av) 2.328(13) 2.325(11)
-2.0 -1.5 -1.0 -0.5 0.0 0.5 1.0
2 A
E / V vs NHE 
μ
Fig. 2. Cyclic voltammogram of 0.2 M 1 in DMSO at a carbon disk working electrode
and a scan rate of 0.2 V/s, starting the scan in cathodic direction.
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signal differs by 38.8 ppm (δ 124.7 ppm for [OsIVCl5(1H-ind)]− and
85.9 ppm for [OsIVCl5(2H-ind)]−). A signiﬁcant downﬁeld shift of C3
resonance in 1 by 99.04 ppm compared to that in [OsIVCl5(1H-ind)]−
at 200.66 ppm is also of note. The shifts of other carbon signals are in
the range from 1.55 to 17.51 ppm (in [OsIVCl5(1H-ind)]− the carbon
resonances are at 75.94 (C9), 81.88 (C7), 106.16 (C5), 139.58 (C4),
163.74 (C6) and 173.67 (C8) ppm) [39].
3.5. Electrochemical behavior
The cyclic voltammograms (CV) of 1 and 2 in DMSO (0.2 M (n-
Bu4N)[BF4]/DMSO) at a carbon disk working electrode, recorded
with a scan rate of 0.2 V/s, display a reversible one-electron reduction
wave attributed to the OsIV→OsIII process with a potential value of
0.03 and 0.13 V for 1 and 2 respectively. Irreversible single electron
reduction wave (Ired) attributed to the OsIII→OsII process is observed
at−1.43 (Fig. 2) and−1.33 V for 1 and 2, correspondingly. The redox
waves OsIV/OsIII for 1 and 2 are characterized by a peak-to-peak sep-
aration (ΔEp) of 74 and 95 mV respectively, and an anodic peak cur-
rent (ipa) that is almost equal to the cathodic peak current (ipc) in
both cases, as expected for a reversible electron transfer process. The
one-electron nature of the electron transfer process was veriﬁed by
comparing the peak current height (ip) with that of the standard300 400 500 600 700 800
0.0
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1.0
1.5
2.0
2.5
3.0
3.5
4.0
A
λ  [nm]
Fig. 3. UV–vis spectra of an aqueous solution of 1 (left) and 2 (rightferrocene/ferrocenium couple under the same experimental condi-
tions. The application of Lever's equation [58] (Eq. (1)) [EL(Cl)=
−0.24 [59], SM(OsIII/OsII)=1.01 [59], and IM(OsIII/OsII)=−0.40 [59]]
E ¼ SM∑EL þ IM ð1Þ
for OsIII→OsII process has allowed the estimate of the yet unknown EL
ligand parameter for 2H-ind tautomer (1, EL=0.18 V), whereas EL li-
gand parameter for 1H-ind tautomer in 2, according to Eq. (1), is
0.28 V. Reported EL value for 1H-ind tautomer is 0.26 V [20].
This ﬁnding demonstrates the increase of the net electron-donor
character (decrease of EL) of 2H-ind tautomer compared to 1H-ind
tautomer, which results in decreased reduction potential of 1.
3.6. UV–vis spectra, aqueous solubility and resistance to hydrolysis
The aqueous solubility of 1 is 1.2 mM at 298 K, compared to
1.3 mM for 2. The aqueous solution behavior of 1 and 2 with respect
to hydrolysis was studied by optical spectroscopy at 294 K over 24 h
(Fig. 3). Both complexes are stable in aqueous solution. Immediate
hydrolysis was excluded since the peak at m/z 485 assigned to
[OsIVCl5(Hind)]−was observed in the negative ion ESI mass spectrum
of the aqueous solution of both 1 and 2 after 24 h. The UV–vis spectra
of 1 and 2 are compared in Fig. 4.
3.7. Solvatochromism
Solvatochromic studies on complexes 1 and 2 have been carried
out by using water and a number of common organic solvents. Com-
plex 1 shows red shifts of the absorption maxima (510–560 nm) in
the following order: DMF>THF>DMSO>H2O (Fig. 5), which is not
strictly in line with the relative permittivity values (εr) of tetrahydro-
furane (7.5) [60], dimethylformamide (37.31) [61], dimethylsulfoxide
(47.2) [62], and water (80.2) [63]. The shift on going from one organic
solvent to another is small relatively to that observed on going from
dimethyl sulfoxide to water. A dramatic increase of the extinction co-
efﬁcient of the mostly long-wavelength absorption in aqueous solu-
tion is also of note. The solvatochromic behavior of 2 is similar. A
red shift on going from organic solvents to water is also clearly
seen, although the extinction coefﬁcients for the red shifted bands
are much lower than for those in 1 (see Supporting Information,
Figs. S5 and S6). The solvatochromic behavior of compounds is usual-
ly explained through different solvation of the ground and excited
states, the positive solvatochromism resulting from better stabiliza-
tion of the excited state by polar solvents. However, this traditional
approach, in which only the equilibrium solvation of the ground
and excited states is taken into account sometimes fails [64–66].300 400 500 600 700 800
λ  [nm]
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), measured immediately after dissolution and 24 h thereafter.
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Fig. 4. UV–vis spectra of aqueous solutions of 1 (dashed black line) and 2 (solid red
line).
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52 G.E. Büchel et al. / Journal of Inorganic Biochemistry 113 (2012) 47–54Therefore, the conclusion about the polarity of the ground and excited
states on the basis of solvatochromic studies is no longer obvious [67].
In the present case the strong red shift of the visible bands in water
solution should be ascribed to a large electric dipole moment in the
excited state in this spectroscopic domain. This implies a large contri-
bution of charge transfer bands in the visible region, which could be
tentatively assigned as involving the electron transfer from indazole
to osmium. Indeed, as can be envisaged from Fig. 1, a variation of
the dipole moment of the order of several Debye could be expected
for such an electron transfer. The nature of the excited states in the
visible region is currently investigated by ab initio calculations.P
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B3.8. Stability and mutual transformation of isomers
The isomeric complexes 1 and 2 were stable in aqueous solution
for at least 24 h (see Section 3.6.) and in dimethyl sulfoxide for at
least 96 h at room temperature. Attempts to induce tautomer conver-
sion by UV irradiation (in ethanolic solution, 150 W Heraeus Noble-
light) resulted in disappearance of the 1H NMR resonances of the
coordinated azole heterocycle after 15 min and in disappearance of
the free indazole signals and formation of ammonium ion after 1 h
of irradiation. Heating 1 and 2 under the conditions used for their
synthesis (see Section 2.2.) for 6 h led to their minor conversionFig. 5. UV–vis spectra of solutions of 1 in H2O (blue), DMSO (red), THF (pink) and DMF
(orange).(less than 10%) into 2 and 1, respectively, according to integration
of the proton resonances. In addition, formation of trace amounts of
[OsCl4(Hind)2] has been detected in solution by NMR spectroscopy.
These data along with the isolation of both isomers from the same
synthesis with comparable yields offer compelling evidence for
close thermodynamic stability and reactivity of both isomers.
3.9. Cytotoxicity in cancer cell lines
The cytotoxicity of 1, in which the ligand adopts the 2H-indazole
tautomeric form, was compared to that of the analogous 1H-indazole
complex 2 by means of the MTT assay in three human cell lines orig-
inating from different malignant tumors. A 96 h exposure yielded the
concentration–effect curves depicted in Fig. 6.
Whereas the curves closely resemble each other in the ovarian
carcinoma cell line CH1 (IC50: 92±20 μM vs 98±23 μM for 1 and 2,
respectively) and the colon carcinoma cell line SW480 (IC50: 100±
15 vs 110±6 μM), those in the non-small cell lung cancer cell line
A549 show differences clearly exceeding the ranges of individual0
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Fig. 6. Concentration–effect curves of (H2ind)[OsIVCl5(2H-ind)] (1) and (H2ind)
[OsIVCl5(1H-ind)] (2) in (A) A549, (B) CH1 and (C) SW480 cells, obtained by the MTT
assay (96 h exposure). Values are means±standard deviations from at least two inde-
pendent experiments.
Fig. 7. Anticancer activity of the 2 in vivo. Hep3B xenografts were grown in Balb/c SCID
mice and treated with 2 (20 mg/kg; i.v.; ﬁve consecutive days per week for 2 weeks).
The effect of treatment on tumor growth on days 25 and 40 are shown: *pb0.05 (stu-
dent's t test, Graph Pad Prism Software).
53G.E. Büchel et al. / Journal of Inorganic Biochemistry 113 (2012) 47–54variations, with 1 being about twice as potent as 2 according to IC50
values (113±17 vs 224±18 μM). Thus, the generally more chemore-
sistant A549 cells are virtually as sensitive to 1 as the other two cell
lines.
Taking into account the aqueous stability of the investigated com-
pounds compared to rapid hydrolysis of ruthenium complexes, the
mechanism of osmium complex cytotoxicity remains an open
question.
3.10. Antiproliferative activity in vivo
Based on our in vitro results, we used a Hep3B SCID mouse xeno-
transplantation model to test the anticancer activity of 1 and 2 in
vivo. In general, the drugs were well tolerated and the mice did not
exhibit any symptoms of toxicity, such as fatigue, or signiﬁcant
weight loss. With regard to the anticancer activity, 2 induced a
minor but signiﬁcant delay in tumor growth (Fig. 7). The mean
tumor volumes were decreased from 300 mm2 to 200 mm2 on day
25 and from 460 mm2 to 290 mm2 on day 40, respectively. In con-
trast, treatment with 1 did not result in lowered tumor mass (data
not shown). Interestingly, however, this compound reduced the inci-
dence of tumor necrosis. While control animals frequently had to be
sacriﬁced due to bleeding of relatively small lesions, tumors in 1-
treated animals exhibited more benign growth leading to enhanced
survival in a subgroup of animals (data not shown).
4. Final remarks
The Anderson type rearrangement of (H2ind)2[OsIVCl6] in ethano-
lic solution yielded two different products, (H2ind)[OsIVCl5(2H-ind)]
and (H2ind)[OsIVCl5(1H-ind)]. The established coordination mode of
2H-indazole via the N1 nitrogen atom in 1 has only one precedence
in the coordination chemistry of indazole. Complexes 1 and 2 exhibit
similar solvatochromic behavior. The cytotoxicity data suggest that
complexes containing 2H-indazole might be advantageous over 1H-
indazole-containing analogs with regard to inhibition of tumor cell
growth in particular cell lines. In contrast to this the in vivo model
showed only tumor growth inhibition for 2 but an interesting reduc-
tion of tumor necrosis and enhanced survival for mice treated with 1.
Efforts by us will be now focused on the synthesis of complexes of 2H-
indazoles and evaluation of their cytotoxicity in order to obtain anti-
tumor drugs, which are more effective than KP1019.Acknowledgment
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Appendix A. Supplementary data
Supporting Information Available: EPR measurement for 1 (Fig.
S1), 15N,1H HSQC,1H,1H COSY and 13C,1H HMBC plots of 1 (Figs. S2–
S4); UV–vis spectra of 2 in THF, MeOH, DMSO, DMF and H2O (Figs.
S5, S6). Crystallographic data for the structure of 1 reported in this
paper have been deposited with the Cambridge Crystallographic
Data Center as supplementary publication no CCDC 865239. Copies
of the data can be obtained free of charge on application to The Direc-
tor, CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: +44-1223-
336-033; e-mail: deposit@ccdc.cam.ac.uk).
Supplementary data to this article can be found online at doi:10.
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